IL2 and neoplasm: Menssen and coauthors reported that in their multiple myeloma model experiments with BALB/C J558L mice, a combination of two immunocytokines, L19-TNFα and L19-IL2, yielded the most effective results, as 75% of animals responded to the therapy, and 58% achieved complete tumor eradication.